middle.news
Why Is FDA Taking Extra Time on Island Pharmaceuticals’ Galidesivir Review?
8:52am on Monday 5th of January, 2026 AEDT
•
Pharmaceuticals
Read Story
Why Is FDA Taking Extra Time on Island Pharmaceuticals’ Galidesivir Review?
8:52am on Monday 5th of January, 2026 AEDT
Key Points
FDA confirms extended review period for Galidesivir clinical development
No adverse feedback or additional data requests from FDA
Galidesivir retains eligibility under Animal Rule and Priority Review Voucher
Preparations for non-human primate study and US government engagement continue
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Island Pharmaceuticals (ASX:ILA)
OPEN ARTICLE